After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and ...

Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The ...

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Soul singer Cissy Houston, who was also known as the mother of pop icon Whitney Houston, died Monday morning. She was 91.

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

Muscae volitantes — “eye floaters” are those little, transparent threads that you see floating across your eyeball. Generally ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said it would cease development of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease due ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s Disease failed to ...